Theravance Biopharma, Inc.TBPH
| Dec 31,
2014 | Dec 31,
2015 | Dec 31,
2016 | Dec 31,
2017 | Dec 31,
2018 | Dec 31,
2019 | Dec 31,
2020 | Dec 31,
2021 | Dec 31,
2022 | Dec 31,
2023 |
|---|
| Viatris collaboration agreement | - | - | - | - | 3 | 14 | 44 | 44 | 49 | 57 |
|---|
| Viatris royalties (Non-US) | - | - | - | - | - | - | - | - | 0 | 0 |
|---|
| Collaboration revenue | - | - | - | - | 42 | 31 | 26 | 11 | 0 | 0 |
|---|
| Licensing revenue | - | - | - | - | - | 29 | 2 | - | 3 | - |
|---|
| Revenues. | 12 | 42 | 49 | 15 | 60 | 73 | 72 | 55 | 51 | 57 |
|---|
| Research and development | 169 | 129 | 142 | 174 | 201 | 219 | 261 | 194 | 63 | 41 |
|---|
| Selling, general and administrative | 72 | 90 | 85 | 96 | 97 | 106 | 109 | 99 | 67 | 70 |
|---|
| Restructuring Charges | - | - | - | - | - | - | - | 20 | 13 | 3 |
|---|
| Total expenses | 244 | 224 | 229 | 276 | 299 | 325 | 370 | 313 | 143 | 113 |
|---|
| Loss from operations | -233 | -182 | -180 | -260 | -239 | -252 | -298 | -258 | -92 | -56 |
|---|
| Interest expense | - | - | 1 | 9 | 10 | 32 | 45 | 47 | 6 | 2 |
|---|
| Loss on extinguishment of debt | - | - | - | - | - | - | -15 | - | -3 | - |
|---|
| Other Nonoperating Income (Expense) | 2 | 1 | 1 | 5 | 12 | 8 | 3 | 1 | 9 | 9 |
|---|
| Loss from continuing operations before income taxes | -231 | -181 | -181 | -272 | -226 | -242 | -287 | -200 | -93 | -49 |
|---|
| Provision for income tax expense | 6 | 1 | 10 | 14 | -11 | -5 | -8 | -0 | 0 | 6 |
|---|
| Net loss from continuing operations | - | - | - | - | - | - | - | - | -93 | -55 |
|---|
| Income from discontinued operations before income taxes | - | - | - | - | - | - | - | - | 1,144 | - |
|---|
| Provision for income tax expense | - | - | - | - | - | - | - | - | 179 | - |
|---|
| Net income from discontinued operations | - | - | - | - | - | - | - | - | 965 | - |
|---|
| Net income (loss) | -237 | -182 | -191 | -285 | -216 | -236 | -278 | -199 | 872 | -55 |
|---|
| Continuing operations - basic (in dollars per share) | - | - | - | - | - | - | - | - | -1.26 | -1 |
|---|
| Continuing operations - diluted (in dollars per share) | - | - | - | - | - | - | - | - | -1.26 | -1 |
|---|
| Discontinued operations - basic (in dollars per share) | - | - | - | - | - | - | - | - | 13.11 | - |
|---|
| Discontinued operations - diluted (in dollars per share) | - | - | - | - | - | - | - | - | 13.11 | - |
|---|
| Earnings Per Share, Basic | - | - | - | - | - | - | - | -2.87 | 11.85 | -1 |
|---|
| Earnings Per Share, Diluted | - | - | - | - | - | - | - | -2.87 | 11.85 | -1 |
|---|
| Total share-based compensation expense | - | 54 | 41 | 49 | 51 | 60 | 63 | 62 | 40 | - |
|---|
| Viatris collaboration agreement | - | - | - | - | 3 | 14 | 44 | 44 | 49 | 57 |
|---|
| Viatris royalties (Non-US) | - | - | - | - | - | - | - | - | 0 | 0 |
|---|
| Collaboration revenue | - | - | - | - | 42 | 31 | 26 | 11 | 0 | 0 |
|---|
| Licensing revenue | - | - | - | - | - | 29 | 2 | - | 3 | - |
|---|
| Revenues. | 12 | 42 | 49 | 15 | 60 | 73 | 72 | 55 | 51 | 57 |
|---|
| Research and development | 169 | 129 | 142 | 174 | 201 | 219 | 261 | 194 | 63 | 41 |
|---|
| Selling, general and administrative | 72 | 90 | 85 | 96 | 97 | 106 | 109 | 99 | 67 | 70 |
|---|
| Restructuring Charges | - | - | - | - | - | - | - | 20 | 13 | 3 |
|---|
| Total expenses | 244 | 224 | 229 | 276 | 299 | 325 | 370 | 313 | 143 | 113 |
|---|
| Loss from operations | -233 | -182 | -180 | -260 | -239 | -252 | -298 | -258 | -92 | -56 |
|---|
| Interest expense | - | - | 1 | 9 | 10 | 32 | 45 | 47 | 6 | 2 |
|---|
| Loss on extinguishment of debt | - | - | - | - | - | - | -15 | - | -3 | - |
|---|
| Other Nonoperating Income (Expense) | 2 | 1 | 1 | 5 | 12 | 8 | 3 | 1 | 9 | 9 |
|---|
| Loss from continuing operations before income taxes | -231 | -181 | -181 | -272 | -226 | -242 | -287 | -200 | -93 | -49 |
|---|
| Provision for income tax expense | 6 | 1 | 10 | 14 | -11 | -5 | -8 | -0 | 0 | 6 |
|---|
| Net loss from continuing operations | - | - | - | - | - | - | - | - | -93 | -55 |
|---|
| Income from discontinued operations before income taxes | - | - | - | - | - | - | - | - | 1,144 | - |
|---|
| Provision for income tax expense | - | - | - | - | - | - | - | - | 179 | - |
|---|
| Net income from discontinued operations | - | - | - | - | - | - | - | - | 965 | - |
|---|
| Net income (loss) | -237 | -182 | -191 | -285 | -216 | -236 | -278 | -199 | 872 | -55 |
|---|
| Continuing operations - basic (in dollars per share) | - | - | - | - | - | - | - | - | -1.26 | -1 |
|---|
| Continuing operations - diluted (in dollars per share) | - | - | - | - | - | - | - | - | -1.26 | -1 |
|---|
| Discontinued operations - basic (in dollars per share) | - | - | - | - | - | - | - | - | 13.11 | - |
|---|
| Discontinued operations - diluted (in dollars per share) | - | - | - | - | - | - | - | - | 13.11 | - |
|---|
| Earnings Per Share, Basic | - | - | - | - | - | - | - | -2.87 | 11.85 | -1 |
|---|
| Earnings Per Share, Diluted | - | - | - | - | - | - | - | -2.87 | 11.85 | -1 |
|---|
| Total share-based compensation expense | - | 54 | 41 | 49 | 51 | 60 | 63 | 62 | 40 | - |
|---|